IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation

BACKGROUND: Continuous combination of MAPK pathway inhibition (MAPKi) and anti-programmed death-(ligand) 1 (PD-(L)1) showed high response rates, but only limited improvement in progression-free survival (PFS) at the cost of a high frequency of treatment-related adverse events (TRAE) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozeman, Elisa A, Versluis, Judith M, Sikorska, Karolina, Hoefsmit, Esmée P, Dimitriadis, Petros, Rao, Disha, Lacroix, Ruben, Grijpink-Ongering, Lindsay G, Lopez-Yurda, Marta, Heeres, Birthe C, van de Wiel, Bart A, Flohil, Claudie, Sari, Aysegul, Heijmink, Stijn W T P J, van den Broek, Daan, Broeks, Annegien, de Groot, Jan Willem B, Vollebergh, Marieke A, Wilgenhof, Sofie, van Thienen, Johannes V, Haanen, John B A G, Blank, Christian U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364170/
https://www.ncbi.nlm.nih.gov/pubmed/37479483
http://dx.doi.org/10.1136/jitc-2023-006821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364170/
https://www.ncbi.nlm.nih.gov/pubmed/37479483
http://dx.doi.org/10.1136/jitc-2023-006821

Ejemplares similares